Bernard Doger M.D., PhD is a Medical Oncologist and member of the medical team of the early phase clinical trials unit, START Madrid-FJD. He completed his medical studies at the Universidad Autónoma de Madrid.

From 2008-2012, he began his specialization in medical oncology at the Hospital Universitario Puerta de Hierro in Madrid.

Subsequently he worked as Regional Medical Liaison (RML) in the medical department of Celgene SL during the developmentof nab-paclitaxel, mainly focused in pancreatic cancer.

Dr. Doger obtained the masters degree in translational oncology from the National Center for Oncological Research (CNIO, Madrid) from 2012-2014. He obtained his PhD Doctorate, with highest commendation in 2019 for his translational research in cancer and targeted therapies by the Universidad San Pablo CEU, Madrid.

In 2015, he joined the START program at START Madrid-CIOCC. One year later, he joined the START Madrid-FJD as a Clinical Researcher dedicated exclusively to early clinical trials and drug development with special focus on targeted therapies, DNA repair, cancer immunotherapy, and adoptive cell therapy. Dr. Doger has been a member of the ethical committee of the Hospital Universitario Fundación Jimenez Díaz since January 2018. He is currently an active Investigator in more than 40 trials and has been co-author of several scientific papers published in medical journals.